Home
|
Inbox
|
Search
|
View Abstract
Major Adverse Cardiovascular Events and Hyperuricemia During Treatment of Tuberculosis
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A5555 - Major Adverse Cardiovascular Events and Hyperuricemia During Treatment of Tuberculosis
Author Block: H. Shin1, J. Chang2, T. Kim1, Y. Kim3, Y. Kwon4; 1Chonnam National University Medical School, Gwangju, Korea, Republic of, 2Chonnam National University Hospital, Gwangju, Korea, Republic of, 3Internal medicine, Chonnam national university hospital, Gwangju, Korea, Republic of, 4Chonnam National University, Gwangju, Korea, Republic of.
Background: Hyperuricemia is common drug effect during treatment of tuberculosis consisting pyrazinamide (PZA). However, it is unclear the relationship between PZA-induced hyperuricemia and major adverse cardiovascular events (MACE). Aim: We evaluated the relationship between MACE and hyperuricemia in patients treated with PZA-based antituberculous drugs. Methods: We retrospectively reviewed the medical charts of patients who treated with tuberculosis at Chonnam National University Hospital between January 2010 and June 2017. Results: Total 1,674 patients were treated with tuberculosis. Among them, 229 patients were excluded due to lack of available serum uric acid levels because of early follow-up loss or local transfer. Mean age was 57.9 and 887 patients (61.4%) were male. Most patients (75.6%) who treated with tuberculosis were diagnosed pulmonary tuberculosis. The initial standard treatment regimens of isoniazid, rifampin, ethambutol, and PZA were introduced to most patients (92.9%). Among them, 61.9% patients at 2 weeks and 59.5% at 2 months from starting treatment had hyperuricemia. MACE were developed only 17 patients (1.2%) during treatment. There was no relationship between hyperuricemia and MACE in the univariate analysis (odds ratio, 0.72; 95% confidence interval, 0.18─2.90; P=0.648). Multivariable analysis with logistic regression revealed that previous ischemic heart disease and diabetes mellitus were risk factors for development of MACE during treatment of tuberculosis. Conclusion: Most patients who received PZA-based antituberculous drugs had hyperuricemia, however, it was not associated with development of MACE.
Author Block: H. Shin1, J. Chang2, T. Kim1, Y. Kim3, Y. Kwon4; 1Chonnam National University Medical School, Gwangju, Korea, Republic of, 2Chonnam National University Hospital, Gwangju, Korea, Republic of, 3Internal medicine, Chonnam national university hospital, Gwangju, Korea, Republic of, 4Chonnam National University, Gwangju, Korea, Republic of.
Background: Hyperuricemia is common drug effect during treatment of tuberculosis consisting pyrazinamide (PZA). However, it is unclear the relationship between PZA-induced hyperuricemia and major adverse cardiovascular events (MACE). Aim: We evaluated the relationship between MACE and hyperuricemia in patients treated with PZA-based antituberculous drugs. Methods: We retrospectively reviewed the medical charts of patients who treated with tuberculosis at Chonnam National University Hospital between January 2010 and June 2017. Results: Total 1,674 patients were treated with tuberculosis. Among them, 229 patients were excluded due to lack of available serum uric acid levels because of early follow-up loss or local transfer. Mean age was 57.9 and 887 patients (61.4%) were male. Most patients (75.6%) who treated with tuberculosis were diagnosed pulmonary tuberculosis. The initial standard treatment regimens of isoniazid, rifampin, ethambutol, and PZA were introduced to most patients (92.9%). Among them, 61.9% patients at 2 weeks and 59.5% at 2 months from starting treatment had hyperuricemia. MACE were developed only 17 patients (1.2%) during treatment. There was no relationship between hyperuricemia and MACE in the univariate analysis (odds ratio, 0.72; 95% confidence interval, 0.18─2.90; P=0.648). Multivariable analysis with logistic regression revealed that previous ischemic heart disease and diabetes mellitus were risk factors for development of MACE during treatment of tuberculosis. Conclusion: Most patients who received PZA-based antituberculous drugs had hyperuricemia, however, it was not associated with development of MACE.
|
Home
|
Inbox
|
Search
|